Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Cash (2017 - 2025)

Historic Change in Cash for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$50.2 million.

  • Denali Therapeutics' Change in Cash fell 41487.12% to -$50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 10323.83%. This contributed to the annual value of $47.9 million for FY2024, which is 15266.61% up from last year.
  • Latest data reveals that Denali Therapeutics reported Change in Cash of -$50.2 million as of Q3 2025, which was down 41487.12% from $84.3 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Change in Cash peaked at $99.4 million during Q4 2022, and registered a low of -$188.5 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Cash was -$20.9 million (2023), whereas its average is -$21.8 million.
  • In the last 5 years, Denali Therapeutics' Change in Cash skyrocketed by 50336.76% in 2024 and then tumbled by 41487.12% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Change in Cash stood at -$101.1 million in 2021, then skyrocketed by 198.37% to $99.4 million in 2022, then crashed by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then crashed by 159.58% to -$50.2 million in 2025.
  • Its last three reported values are -$50.2 million in Q3 2025, $84.3 million for Q2 2025, and -$116.5 million during Q1 2025.